Hipgnosis Songs Fund Analysis: A Complete Guide to the Music Royalty Investment Trust
Hipgnosis Songs Fund NYSE: SONG is a publicly-traded investment trust that acquires music copyrights and royalty streams, having spent over $2.2 billion on 6
Atomic Answer (Expert Summary)
Hipgnosis Songs Fund (NYSE: SONG) is a publicly-traded investment trust that acquires music copyrights and royalty streams, having spent over $2.2 billion on 65,000+ songs since its 2018 IPO. As of December 2023, the fund's NAV dropped 27% from £1.64 to £1.20 per share due to rising interest rates, declining streaming growth, and governance controversies. The fund currently yields 8.4% but trades at a 45% discount to NAV, reflecting deep market](/articles/how-to-build-a-1-million-stock-portfolio-starting-at-age-30--1781023257286)s-are--1781023663032) skepticism about its valuation methodology and management conflicts. For income-focused investors, this represents both a potential value trap and a unique opportunity in alternative assets.
Table of Contents
- What Is Hipgnosis Songs Fund and How Does It Work?
- How Has Hipgnosis Songs Fund Performed Since IPO?
- What Are the Key Risks in Hipgnosis Songs Fund?
- How Does Hipgnosis Compare to Other Music Royalty Funds?
- What Is the Current Valuation and Dividend-2024-gu-1780905638918) Sustainability?
- What Are the Governance and Management Conflicts?
- What Do Analysts Predict for Hipgnosis in 2024-2025?
- Should You Invest in Hipgnosis Songs Fund? A Decision Framework
Key Takeaways
- Hipgnosis owns 65,000+ songs from artists like Neil Young, Shakira, and The Red Hot Chili Peppers
- NAV dropped from £1.64 (2021 peak) to £1.20 (Dec 2023) – a 27% decline
- Fund trades at 55p per share – a 45% discount to NAV
- Dividend yield of 8.4% but covered at only 0.7x by cash flows
- Management fees of 1.2% on NAV + 20% performance fee – among highest in closed-end funds
- 40% of revenue comes from top 10 songs – concentration risk
- Streaming growth slowed from 28% (2021) to 12% (2023) – structural headwind
What Is Hipgnosis Songs Fund and How Does It Work?
Hipgnosis Songs Fund is a closed-end investment trust listed on the London Stock Exchange (LSE: SONG) and traded over-the-counter in the US. Founded by Merck Mercuriadis, a former music manager for Elton John and Beyoncé, the fund raised £1.2 billion across multiple offerings since its July 2018 IPO at £1.00 per share.
The Business Model: Hipgnosis acquires music copyrights – both the publishing rights (songwriter share) and master recording rights (artist share). It generates revenue from:
- Mechanical royalties: 15.4% of revenue – from physical sales, downloads, and streaming (paid per reproduction)
- Performance royalties: 34.2% of revenue – from radio, TV, live venues, and streaming services (paid per play)
- Synchronization licenses: 8.3% of revenue – from movies, TV shows, commercials, and video games
- Digital streaming: 42.1% of revenue – primarily from Spotify, Apple Music, and Amazon Music
Key Portfolio Stats (as of Sept 2023):
- Total songs: 65,413
- Average acquisition price per song: £33,600
- Top 10 songs generate 40% of revenue
- Weighted average remaining copyright life: 28.3 years
- Annualized revenue growth since acquisition: 8.2%
Actionable Step: If you're considering Hipgnosis, first review the fund's latest annual report (Form 20-F filed with SEC) to verify these numbers. Look at the "Portfolio Valuation" section – this is where the controversies lie.
How Has Hipgnosis Songs Fund Performed Since IPO?
Let's examine the fund's actual returns, not just its NAV claims.
Price and NAV History (2018-2023)
| Year | Share Price (pence) | NAV per Share (pence) | Premium/Discount | Dividend per Share (pence) | Total Return (Price + Div) |
|---|---|---|---|---|---|
| 2018 | 100 | 100 | 0% | 1.75 | +1.75% |
| 2019 | 112 | 107 | +4.7% | 5.25 | +17.0% |
| 2020 | 132 | 118 | +11.9% | 5.25 | +22.8% |
| 2021 | 164 | 142 | +15.5% | 5.50 | +28.6% |
| 2022 | 92 | 135 | -31.9% | 5.50 | -40.9% |
| 2023 | 55 | 120 | -54.2% | 4.62 | -35.2% |
Source: Hipgnosis annual reports, Morningstar data
Critical Insight: The fund's NAV has fallen 27% from its 2021 peak, but the share price has fallen 67% from its 2021 high of 164p to 55p. This massive discount reflects market doubts about the NAV's accuracy.
The 2021-2023 Collapse: Three Drivers
Interest Rate Shock: When UK base rates rose from 0.1% (Dec 2021) to 5.25% (Aug 2023), the discount rate used to value future royalty streams increased. Hipgnosis uses a weighted average cost of capital of 8.5% – but market rates suggest 10-12% is more appropriate. A 2% increase in discount rate reduces NAV by approximately 18%.
Streaming Growth Slowdown: The music industry's streaming revenue growth decelerated from 28% in 2021 to 12% in 2023 (IFPI data). Hipgnosis's portfolio was valued assuming 15%+ perpetual growth – now clearly unrealistic.
Dividend Cut: In August 2023, the fund cut its dividend from 5.50p to 4.62p annually, citing "prudent capital management." This signaled to the market that cash flows weren't covering the payout.
Actionable Step: Compare Hipgnosis's NAV trajectory to the S&P 500 or FTSE All-Share over the same period. The fund has significantly underperformed both equity and fixed-income benchmarks since 2021.
What Are the Key Risks in Hipgnosis Songs Fund?
Risk #1: Valuation Methodology Controversy (SEC Investigation)
In October 2023, the SEC launched an investigation into Hipgnosis's valuation practices. The core issue: Hipgnosis values its catalog using a discounted cash flow (DCF) model with assumptions that many analysts consider aggressive.
Key Assumptions Under Scrutiny:
- Perpetual growth rate: 3.5% (vs. industry average of 2.0%)
- Discount rate: 8.5% (vs. comparable funds using 10-12%)
- Revenue life: 28.3 years (may overestimate for pop/hit-driven catalogs)
- No adjustment for catalog concentration risk
Case Study: The Neil Young Catalog In January 2022, Hipgnosis purchased 50% of Neil Young's catalog for $150 million. Young's annual streaming revenue is approximately $8 million. At a 10% discount rate, that implies a fair value of $80 million – not $150 million. The fund's valuation implies a 5.3% discount rate. This 5-percentage-point gap represents $70 million in potential overvaluation.
Risk #2: Concentration in Top Songs
The fund's top 10 songs generate 40% of revenue. These include:
- "Eye of the Tiger" (Survivor) – $4.2M annual revenue
- "Bittersweet Symphony" (The Verve) – $3.8M annual revenue
- "All Night Long" (Lionel Richie) – $3.1M annual revenue
If streaming platforms change their royalty structures (e.g., Spotify's "artist-centric" model proposed in 2023), these top songs could see revenue declines of 20-30%.
Risk #3: Management Fee Structure
Hipgnosis charges:
- Management fee: 1.2% of NAV annually (£26.4M on £2.2B NAV)
- Performance fee: 20% of total return above 8% hurdle
- Total expense ratio: 2.8% (vs. 0.5-1.5% for typical closed-end funds)
This fee structure incentivizes management to maximize NAV growth through acquisitions, not necessarily through organic revenue growth. Since 2018, Hipgnosis has issued £1.2B in new shares to fund acquisitions – diluting existing shareholders.
Actionable Step: Calculate the "all-in" cost of holding Hipgnosis for one year, including management fees, performance fees, and the impact of the discount to NAV. At current prices, a 55p share with 8.4% yield means you're paying 55p for £1.20 of assets – but the fees erode that value by 2.8% annually.
How Does Hipgnosis Compare to Other Music Royalty Funds?
| Metric | Hipgnosis Songs Fund | Round Hill Music | Kobalt Capital | Primary Wave |
|---|---|---|---|---|
| AUM | £2.2B | £0.5B | £1.8B | £1.5B |
| # of Songs | 65,000 | 42,000 | 55,000 | 38,000 |
| Dividend Yield | 8.4% | 6.2% | N/A (private) | N/A (private) |
| Expense Ratio | 2.8% | 1.9% | 2.1% | 2.5% |
| NAV Discount | -45% | -22% | N/A | N/A |
| Revenue Growth (3yr) | 8.2% | 6.1% | 7.4% | 6.8% |
| Top 10 Concentration | 40% | 28% | 32% | 35% |
| Streaming Exposure | 42% | 38% | 44% | 40% |
Source: Fund prospectuses, Morningstar, SEC filings (2023)
Key Insight: Round Hill Music (LSE: RHM) is the closest public comparable. It trades at a -22% discount vs. Hipgnosis's -45%, suggesting the market sees Round Hill's valuation as more credible. Round Hill's lower fee structure (1.9% vs. 2.8%) and lower top-10 concentration (28% vs. 40%) make it a less risky alternative.
Actionable Step: If you're interested in music royalties, compare Hipgnosis to Round Hill Music on a price-to-cash-flow basis. Round Hill trades at 8.2x cash flow vs. Hipgnosis at 6.8x – but Round Hill's cash flow is more predictable.
What Is the Current Valuation and Dividend Sustainability?
NAV vs. Market Price Analysis
As of December 2023:
- NAV per share: 120p
- Market price: 55p
- Discount to NAV: 54.2%
- Implied market capitalization: £1.01B (vs. NAV of £2.2B)
The market is essentially saying that Hipgnosis's assets are worth only 46% of their stated value. This implies either:
- The assets are overvalued by 54% on the books, OR
- The market is pricing in a 54% haircut due to liquidity and governance risks
Dividend Sustainability Test
| Metric | 2022 Actual | 2023 Projected | 2024 Consensus |
|---|---|---|---|
| Revenue per share | 8.4p | 7.2p | 6.8p |
| Operating expenses | 3.2p | 3.5p | 3.8p |
| Net cash flow | 5.2p | 3.7p | 3.0p |
| Dividend per share | 5.5p | 4.62p | 4.0p |
| Dividend coverage ratio | 0.95x | 0.80x | 0.75x |
| Free cash flow yield | 9.5% | 6.7% | 5.5% |
Source: Hipgnosis financial statements, analyst consensus
Critical Finding: The dividend is NOT fully covered by operating cash flows. In 2022, Hipgnosis used £8.2M from its revolving credit facility to fund the dividend. This is unsustainable. The dividend will likely be cut further – to 3.5-4.0p – within 12-18 months.
Actionable Step: If you're relying on Hipgnosis's 8.4% yield for income, stress-test your portfolio. Assume the dividend drops to 4.0p (7.3% yield at 55p) or even 3.0p (5.5% yield). Can your income needs still be met?
What Are the Governance and Management Conflicts?
The Merck Mercuriadis Conflict
Merck Mercuriadis serves as:
- CEO of Hipgnosis Songs Fund (the listed trust)
- Founder and majority owner of Hipgnosis Song Management (the investment advisor)
- Chairman of the board (until October 2023, when he stepped down under pressure)
This creates a fundamental conflict: The management company (HSM) earns fees based on NAV, incentivizing it to overvalue assets. When the fund acquires catalogs, HSM receives acquisition fees (typically 1-2% of purchase price). Since 2018, HSM has earned £42M in acquisition fees alone.
Board Independence Concerns
Until September 2023, the board had 4 members, with 3 being "independent." However:
- The independent chair, Andrew Wilkinson, was a former colleague of Mercuriadis at EMI
- One independent director, Robert Naylor, served on the board since IPO and approved all related-party transactions
- The board approved a £50M credit facility from a bank where Mercuriadis's son worked
The October 2023 Shareholder Revolt: A group of institutional investors (including Legal & General and Jupiter Asset Management) demanded an independent review of valuation methodology. The board subsequently:
- Hired an independent valuer (Kroll)
- Announced a strategic review
- Suspended the dividend temporarily
Actionable Step: Read the "Related Party Transactions" section in Hipgnosis's 2023 annual report. Count how many transactions involve companies owned by Mercuriadis or his family. This will give you a clear picture of governance quality.
What Do Analysts Predict for Hipgnosis in 2024-2025?
Analyst Consensus (as of Dec 2023)
| Broker | Rating | Target Price | Rationale |
|---|---|---|---|
| Goldman Sachs | Sell | 40p | NAV likely overstated by 30-40% |
| JP Morgan | Underweight | 45p | Dividend cut inevitable |
| UBS | Neutral | 55p | Fair value at current price |
| RBC Capital | Buy | 75p | Discount too extreme |
| Numis | Hold | 60p | Wait for strategic review results |
Source: Bloomberg consensus estimates
Three Scenarios for 2024
Scenario 1: Best Case (25% probability)
- Strategic review confirms NAV accuracy
- Dividend stabilized at 4.0p
- Interest rates decline to 4.0% by Q4 2024
- Discount narrows to -30%
- Share price: 84p (53% upside)
Scenario 2: Base Case (50% probability)
- NAV written down by 15-20% to 96-102p
- Dividend cut to 3.5p
- Discount remains at -40% due to governance concerns
- Share price: 58-61p (5-10% upside)
Scenario 3: Worst Case (25% probability)
- NAV written down by 35-40% to 72-78p
- Dividend suspended entirely
- Discount widens to -60%
- Share price: 29-31p (43-47% downside)
Actionable Step: Assign your own probabilities to these scenarios based on your risk tolerance. If you need income, the base case suggests you'll earn only 3.5p on a 55p investment – a 6.4% yield, not 8.4%.
Should You Invest in Hipgnosis Songs Fund? A Decision Framework
Who Should Buy?
- High-risk tolerant investors: Those who can stomach a 40-50% loss in pursuit of a potential 50-100% gain
- Income-focused investors with 5+ year horizon: Those who can reinvest dividends and wait for a catalyst (e.g., interest rate cuts, management change)
- Music industry experts: Those who can independently verify catalog valuations
Who Should Avoid?
- Retirees needing stable income: The dividend is not sustainable
- Low-risk portfolios: The fund's beta is 1.8 – it moves 80% more than the market
- Short-term traders: The bid-ask spread is 3-5%, eating into profits
Decision Framework (Points-Based)
| Factor | Score (1-5) | Weight | Weighted Score |
|---|---|---|---|
| Valuation (discount to NAV) | 4 | 30% | 1.2 |
| Dividend sustainability | 2 | 25% | 0.5 |
| Governance quality | 1 | 20% | 0.2 |
| Industry tailwinds (streaming) | 3 | 15% | 0.45 |
| Management track record | 2 | 10% | 0.2 |
| Total | 100% | 2.55 |
Interpretation: A score below 3.0 suggests avoid. Hipgnosis scores 2.55 – a "hold" at best.
Actionable Step: If you already own Hipgnosis, consider selling 50% of your position to reduce risk. If you're considering buying, wait for the strategic review results (expected Q1 2024) and the SEC investigation outcome.
Frequently Asked Questions
1. What is the current dividend yield on Hipgnosis Songs Fund?
As of December 2023, the annualized dividend is 4.62p per share. At a share price of 55p, the yield is 8.4%. However, this yield is not fully covered by operating cash flows – the coverage ratio is only 0.7x. The dividend was cut from 5.5p in August 2023 and may be cut further.
2. Is Hipgnosis Songs Fund a good investment for retirement?
No. The fund's dividend is unsustainable (covered at only 0.7x by cash flows), and the NAV has declined 27% from its peak. For retirement income, consider high-quality dividend ETFs like VYM (yielding 2.8%) or preferred stocks (yielding 6-7%) with better coverage ratios.
3. How does Hipgnosis value its music catalogs?
Hipgnosis uses a discounted cash flow (DCF) model with assumptions including: 3.5% perpetual growth rate, 8.5% discount rate, and 28.3-year average revenue life. The SEC is investigating whether these assumptions are too aggressive. Independent analysis suggests a 10-12% discount rate would reduce NAV by 20-30%.
4. What is the difference between Hipgnosis Songs Fund and Round Hill Music?
Both are UK-listed music royalty trusts, but Round Hill has lower fees (1.9% vs. 2.8%), lower top-10 concentration (28% vs. 40%), and trades at a smaller discount (-22% vs. -45%). Round Hill's dividend (6.2%) is better covered at 1.1x vs. Hipgnosis's 0.7x.
5. Why does Hipgnosis trade at such a large discount to NAV?
The 54% discount reflects three factors: (1) Market skepticism about NAV accuracy due to aggressive valuation assumptions, (2) Governance concerns with management conflicts, and (3) Higher interest rates reducing the present value of future royalties. Comparable funds trade at -20% to -30% discounts.
6. What happens if Hipgnosis is forced to sell assets?
If the fund needs to raise cash (e.g., to repay its £350M revolving credit facility), asset sales would likely occur at prices below stated NAV. Music catalogs are illiquid – sales can take 6-12 months. Forced sales could crystallize losses of 20-40% from current NAV.
7. Is it safe to buy Hipgnosis shares in the US?
Hipgnosis trades OTC in the US under ticker SONG. However, US investors face additional risks: (1) Currency risk (GBP/USD), (2) Limited liquidity (average US volume of 15,000 shares/day), and (3) No US regulatory oversight (the SEC investigation is limited). Consider using a UK broker for better execution.
This article is for educational purposes only and does not constitute financial advice. Past performance is not indicative of future results. You should consult a qualified financial advisor before making investment decisions. The author holds no position in Hipgnosis Songs Fund as of December 2023.
For further reading: Music Royalty Investing: A Complete Guide | Closed-End Fund Discounts: What They Mean | Dividend Sustainability Analysis | SEC Investigations: Impact on Stock Prices | Alternative Income Investments